Moderna Stock: Buy at the High?
Moderna (NASDAQ: MRNA) shares have soared by more than 768% this year. Right now, they're sitting at an all-time high. The clinical-stage biotech company was among the first to leap into the coronavirus vaccine race earlier this year, and the clinical trial data from its candidate, mRNA-1273, has been overwhelmingly positive. After the primary analysis of its phase 3 trial, Moderna's vaccine candidate was found to be 94.1% effective at preventing COVID-19.
Now, Moderna may be only days away from receiving an emergency use authorization (EUA) from the FDA for its investigational vaccine. At this point, you might have mixed feelings about getting in on this stock. You may want to buy the shares because vaccine revenue is right around the corner, but feel wary about investing at today's valuations.
Image source: Getty Images.
Source Fool.com
